Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6031
Peer-review started: May 13, 2023
First decision: July 4, 2023
Revised: July 21, 2023
Accepted: August 9, 2023
Article in press: August 9, 2023
Published online: September 16, 2023
Processing time: 117 Days and 22.2 Hours
Fasting during the month of Ramadan is one of the five fundamental principles of Islam, and it is obligatory for healthy Muslim adults and adolescents. During the fasting month, Muslims usually have two meals a day, suhur (before dawn) and iftar (after dusk). However, diabetic patients may face difficulties when fasting, so it is important for medical staff to educate them on safe fasting practices. Prolonged strict fasting can increase the risk of hypoglycemia and diabetic ketoacidosis, but with proper knowledge, careful planning, and medication adjustment, diabetic Muslim patients can fast during Ramadan. For this review, a literature search was conducted using PubMed and Google Scholar until May 2023. Articles other than the English language were excluded. Current strategies for managing blood sugar levels during Ramadan include a combination of patient education on nutrition, regular monitoring of blood glucose, medications, and insulin therapy. Insulin therapy can be continued during fasting if properly titrated to the patients’ needs, and finger prick blood sugar levels should be assessed regularly. If certain symptoms such as hypoglycemia, hyperglycemia, dehydration, or acute illness occur, or blood glucose levels become too high (> 300 mg/dL) or too low (< 70 mg/dL), the fast should be broken. New insulin formu
Core Tip: During Ramadan, most Muslims have two meals a day: Suhur (before dawn) and iftar (after dusk). Medical staff should educate Muslim patients on safe fasting to ease difficulties for diabetic patients. Controlling blood sugar levels involves a multi-pronged approach with patient education, monitoring, medications, and insulin. Insulin therapy can be continued during fasting if adjusted to the patients’ needs. New medications like pegylated insulin, dual agonists, and sodium-glucose cotransporter 2 inhibitors offer additional cardiovascular benefits for diabetic patients.